Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer’s Disease and Correlates with Cognitive Impairment

Patrick Oeckl(University Hospital Ulm), Steffen Halbgebauer(University Hospital Ulm), Sarah Anderl‐Straub(University Hospital Ulm), Petra Steinacker(University Hospital Ulm), André Huss(University Hospital Ulm), Hermann Neugebauer(University Hospital Ulm), Christine A. F. Von Arnim(University Hospital Ulm), Janine Diehl‐Schmid(TUM Klinikum), Timo Grimmer(TUM Klinikum), Johannes Kornhuber(Friedrich-Alexander-Universität Erlangen-Nürnberg), Piotr Lewczuk(Medical University of Białystok), Adrian Danek(LMU Klinikum), Albert C. Ludolph(University Hospital Ulm), Markus Otto(University Hospital Ulm)
Journal of Alzheimer s Disease
December 24, 2018
10.3233/jad-180325
Cited by 358

Abstract

Reliable blood biomarkers for Alzheimer's disease (AD) are missing. We measured astroglial GFAP in patients with AD (n = 28), frontotemporal dementia (bvFTD, n = 35), Parkinson's disease (n = 11), Lewy body dementias (n = 19), and controls (n = 34). Serum GFAP was increased in AD (p < 0.001) and DLB/PDD (p < 0.01), and cerebrospinal fluid GFAP was increased in all neurodegenerative diseases (p < 0.001). Serum GFAP correlated with the Mini-Mental State Examination score (r= -0.42, p < 0.001) and might be a follow-up marker in clinical trials. Sensitivity and specificity of serum GFAP for AD versus bvFTD was 89% and 79% and might be the first blood biomarker in the differential diagnosis of AD and bvFTD.

Related Papers

No related papers found

Powered by citation graph analysis